| Literature DB >> 26423571 |
Sigita Petraitiene1,2, Tomas Alasevicius3,4, Indre Staceviciene5,6, Daiva Vaiciuniene7, Tomas Kacergius8, Vytautas Usonis9,10.
Abstract
BACKGROUND: Streptococcus pneumoniae (SPn) is an important pathogen causing a variety of clinical manifestations. The effects of SPn nasopharyngeal colonization on respiratory tract infections are poorly studied. We evaluated the association of SPn colonization with features of respiratory tract infections.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26423571 PMCID: PMC4589981 DOI: 10.1186/s12879-015-1149-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic specifics of the study population
| Site | Total | ||||||
|---|---|---|---|---|---|---|---|
| EDa | Vilnius | Kaunas | Panevėžys | Alytus | Klaipėda | ||
| Samples, n | 264 | 173 | 159 | 223 | 18 | 63 | 900 |
| Positive samplesb, | 121 (45.8) | 86 (49.7) | 52 (32.7) | 82 (36.8) | 2 (11.1) | 24 (38.1) | 367 (40.8) |
| Mean age, months (SD) | 33.52 (16.45) | 32.32 (16.33) | 34.35 (18.84) | 37.91 (17.57) | 49.13 (15.37) | 39.00 (18.57) | 35.20 (17.45) |
| Males, | 154 (58.3) | 89 (51.5) | 81 (50.9) | 120 (53.8) | 14 (77.8) | 34 (54.0) | 492 (54.7) |
| Females, | 110 (41.7) | 84 (48.5) | 78 (49.1) | 103 (46.2) | 4 (22.2) | 29 (46.0) | 408 (45.3) |
| DCC attendance, | 149 (56.7) | 110 (64.7) | 113 (71.1) | 177 (79.4 %) | 14 (87.5) | 45 (73.8) | 608 (67.6) |
| Antimicrobial use, | 98 (39.2) | 74 (43.3) | 59 (37.3) | 112 (50.2) | 1 (12.5) | 17 (28.8) | 361 (40.1) |
aED–Emergency Department of Children’s Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos. b Positive nasopharyngeal samples for Streptococcus pneumoniae
Prevalence of SPn colonization in relation to various factors during respiratory tract infection
| Characteristic | Colonized ( | Non-colonized ( | PR (95 % CI) |
| |
|---|---|---|---|---|---|
| Age (months) a: | <24c | 90 | 158 | ||
| 24–47 | 196 | 222 | 1.050 (0.813–1.356) | 0.840 | |
| 48–71 | 75 | 137 | 0.736 (0.542–0.999) | 0.049 | |
| Sex | Male | 199 | 293 | 0.982 (0.939–1.150) | 0.824 |
| Femalec | 168 | 240 | |||
| Siblings | 145 | 189 | 1.114 (0.949–1.308) | 0.187 | |
| DCC attendanceb | 270 | 338 | 1.423 (1.105–1.832) | 0.006 | |
| Signs and symptoms: | Coryza | 276 | 390 | 0.962 (0.753–1.230) | 0.757 |
| Cough | 240 | 331 | 1.133 (0.884–1.452) | 0.323 | |
| Fever | 213 | 304 | 0.919 (0.740–1.143) | 0.449 | |
| Tonsils | 191 | 260 | 1.074 (0.882–1.308) | 0.478 | |
| Auscultation | 62 | 102 | 1.391 (0.881–2.197) | 0.157 | |
| Throat | 295 | 416 | 1.087 (0.693–1.704) | 0.716 | |
| Recovery: | 1–2 weeksc | 213 | 382 | ||
| 3–4 weeks | 114 | 98 | 1.502 (1.274–1.771) | < 0.001 | |
| > 4 weeks | 8 | 12 | 1.117 (0.646–1.932) | 0.691 | |
| Antimicrobial use | 204 | 157 | 1.901 (1.618–2.234) | < 0.001 | |
| Diagnoses | URTIc | 208 | 384 | ||
| Bronchitis | 62 | 51 | 1.562 (1.279–1.907) | < 0.001 | |
| Pneumonia | 14 | 10 | 1.660 (1.164–2.369) | 0.005 | |
| Sinusitis | 23 | 13 | 1.818 (1.390–2.379) | < 0.001 | |
| AOM | 35 | 41 | 1.311 (1.004–1.712) | 0.047 | |
| Others | 5 | 7 | 1.186 (0.602–2.337) | 0.622 | |
| Non-specified | 20 | 27 | 1.211 (0.854–1.718) | 0.283 |
PR (95 % CI)–prevalence ratio and 95 % confidence interval of Streptococcus pneumoniae nasopharyngeal colonization
Coryza–nasal secretion and/or nasal congestion
Fever–body temperature above 37.0 °C
Throat–signs of inflammation of the throat, including redness, oedema, and papules
Tonsils–signs of inflammation of the palatine tonsils, including redness, oedema, coating, and blisters
Auscultation–auscultation of the lungs, including signs of obstruction, rales, and crackles
aAdjusted for DCC attendance
bAdjusted for age
cRefference group for each comparison
Fig. 1Recovery duration based on Streptococcus pneumoniae serotype/serogroup. Only serotypes with at least 10 cases are displayed. Recovery duration (1–2 vs 3–4 weeks vs longer than 4 weeks) for each serotype/serogroup compared with SPn-negative group (chi-squared test). 15–serogroup 15. 23–non-23F serotypes
Frequencies of diagnoses per Streptococcus pneumoniae serotype and use of antimicrobials per diagnosis
| Diagnosis, | Total, | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Unspecified | Other | AOM | URTI | Sinusitis | Pneumonia | Bronchitis | |||
| Serotype | None | 27 (5.1) | 7 (1.3) | 41 (7.7) | 384 (72.0) | 13 (2.4) | 10 (1.9) | 51 (9.6) | 533 (59.2) |
| Othera | 1 (4.0) | 0 (0.0) | 3 (12.0) | 13 (52.0) | 4 (16.0) | 1 (4.0) | 3 (12.0) | 25 (2.7) | |
| 11 | 0 (0.0) | 2 (11.8) | 0 (0.0) | 9 (52.9) | 0 (0.0) | 0 (0.0) | 6 (35.3) | 17 (1.9) | |
| 14 | 2 (5.7) | 0 (0.0) | 3 (8.6) | 15 (42.9) | 2 (5.7) | 5 (14.3) | 8 (22.9) | 35 (3.8) | |
| 15b | 2 (5.4) | 0 (0.0) | 3 (8.1) | 25 (67.6) | 1 (2.7) | 2 (5.4) | 4 (10.8) | 37 (4.1) | |
| 18C | 2 (18.2) | 0 (0.0) | 2 (18.2) | 5 (45.5) | 1 (9.1) | 0 (0.0) | 1 (9.1) | 11 (1.2) | |
| 19A | 1 (12.5) | 1 (12.5) | 0 (0.0) | 4 (50.0) | 1 (12.5) | 0 (0.0) | 1 (12.5) | 8 (0.9) | |
| 19F | 4 (7.8) | 0 (0.0) | 9 (17.6) | 25 (49.0) | 3 (5.9) | 1 (2.0) | 9 (17.6) | 51 (5.6) | |
| 23c | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (50.0) | 3 (30.0) | 0 (0.0) | 2 (20.0) | 10 (1.1) | |
| 23F | 1 (2.0) | 0 (0.0) | 1 (2.0) | 35 (68.6) | 5 (9.8) | 2 (3.9) | 7 (13.7) | 51 (5.7) | |
| 3 | 1 (9.1) | 0 (0.0) | 3 (27.3) | 4 (36.4) | 1 (9.1) | 0 (0.0) | 2 (18.2) | 11 (1.2) | |
| 6A | 2 (5.9) | 0 (0.0) | 6 (17.6) | 19 (55.9) | 1 (2.9) | 1 (2.9) | 5 (14.7) | 34 (3.8) | |
| 6B | 3 (5.2) | 2 (3.4) | 4 (6.9) | 33 (56.9) | 1 (1.7) | 2 (3.4) | 13 (22.4) | 58 (6.4) | |
| Non-typable | 1 (5.2) | 0 (0.0) | 1 (5.3) | 16 (84.2) | 0 (0.0) | 0 (0.0) | 1 (5.2) | 19 (2.1) | |
| Total, | 47 (5.2) | 12 (1.3) | 76 (8.4) | 592 (65.8) | 36 (4.0) | 24 (2.7) | 113 (12.6) | 900 (100.0) | |
| Antimicrobial use, | 14 (29.7) | 3 (25.0) | 55 (72.4) | 173 (29.2) | 32 (88.8) | 23 (95.8) | 61 (12.6) | 361 (40.1) | |
AOM acute otitis media, URTI upper respiratory tract infection
aCombined cases of SPn serotypes 4, 7, 7F, 6C, 9, 9V, 10, 12, 17, 19, 22
bSerogroup 15
cNon-23F serotypes
Fig. 2Use of antimicrobials based on Streptococcus pneumoniae serotype/serogroup. Only serotypes with at least 10 cases are displayed. Antimicrobial use (used vs not used) for each serotype/serogroup compared with SPn-negative group (chi-squared test). 15–serogroup 15. 23–non-23F serotypes